Clinical Significance of TWIST-Positive Circulating Tumor Cells in Patients with Esophageal Squamous Cell Carcinoma.
Circulating tumor cells
Esophageal neoplasms
Squamous cell carcinoma
TWIST
Journal
Gut and liver
ISSN: 2005-1212
Titre abrégé: Gut Liver
Pays: Korea (South)
ID NLM: 101316452
Informations de publication
Date de publication:
15 07 2021
15 07 2021
Historique:
received:
20
06
2020
revised:
25
08
2020
accepted:
02
09
2020
pubmed:
10
12
2020
medline:
25
2
2023
entrez:
9
12
2020
Statut:
ppublish
Résumé
Unlike other gastrointestinal tract cancers, there are relatively few reports on the clinical significance of circulating tumor cells (CTCs) and TWIST, a marker of epithelial-mesenchymal transition, in patients with esophageal squamous cell carcinoma (ESCC). This study aimed to evaluate the clinical significance of TWIST expression in CTCs in patients with ESCC. Peripheral blood samples for CTC analyses were prospectively obtained from 52 patients with ESCC prior to treatment between September 2017 and September 2019. CTCs were detected using a centrifugal microfluidic system based on a fluid-assisted separation technique, and CTCs positive for TWIST on immunostaining were defined as TWIST (+) CTCs. Of the 52 patients with ESCC, CTCs and TWIST (+) CTCs were detected in 44 patients (84.6%) and 39 patients (75.0%), respectively. The CTC and TWIST (+) CTC counts were significantly higher in patients aged >65 years and those who had a large tumor (>3 cm) than in those aged ≤65 years and those who had a small tumor (≤3 cm), respectively. There were no differences in CTC and TWIST (+) CTC counts according to tumor location, histologic grade, or TNM stage. TWIST (+) CTCs were significantly associated with histologic grade; a proportion of TWIST (+) CTCs ≥0.5 was significantly associated with advanced histologic grade. Other clinicopathologic characteristics such as sex, age, tumor location, tumor size, and TNM stages were not significantly associated with TWIST (+) CTCs. Our study showed that TWIST (+) CTCs were frequently detected in patients with ESCC, and a high proportion of TWIST (+) CTCs was associated with poor differentiation.
Sections du résumé
Background/Aims
Unlike other gastrointestinal tract cancers, there are relatively few reports on the clinical significance of circulating tumor cells (CTCs) and TWIST, a marker of epithelial-mesenchymal transition, in patients with esophageal squamous cell carcinoma (ESCC). This study aimed to evaluate the clinical significance of TWIST expression in CTCs in patients with ESCC.
Methods
Peripheral blood samples for CTC analyses were prospectively obtained from 52 patients with ESCC prior to treatment between September 2017 and September 2019. CTCs were detected using a centrifugal microfluidic system based on a fluid-assisted separation technique, and CTCs positive for TWIST on immunostaining were defined as TWIST (+) CTCs.
Results
Of the 52 patients with ESCC, CTCs and TWIST (+) CTCs were detected in 44 patients (84.6%) and 39 patients (75.0%), respectively. The CTC and TWIST (+) CTC counts were significantly higher in patients aged >65 years and those who had a large tumor (>3 cm) than in those aged ≤65 years and those who had a small tumor (≤3 cm), respectively. There were no differences in CTC and TWIST (+) CTC counts according to tumor location, histologic grade, or TNM stage. TWIST (+) CTCs were significantly associated with histologic grade; a proportion of TWIST (+) CTCs ≥0.5 was significantly associated with advanced histologic grade. Other clinicopathologic characteristics such as sex, age, tumor location, tumor size, and TNM stages were not significantly associated with TWIST (+) CTCs.
Conclusions
Our study showed that TWIST (+) CTCs were frequently detected in patients with ESCC, and a high proportion of TWIST (+) CTCs was associated with poor differentiation.
Identifiants
pubmed: 33293482
pii: gnl20194
doi: 10.5009/gnl20194
pmc: PMC8283289
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
553-561Références
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Clin Exp Metastasis. 2009;26(8):1025-32
pubmed: 19816777
J Exp Clin Cancer Res. 2009 Dec 21;28:158
pubmed: 20025748
Cancer Biol Ther. 2012 Jun;13(8):606-13
pubmed: 22441818
Cancer. 2017 Nov 1;123(21):4106-4113
pubmed: 28885712
Ann Surg. 2015 Jun;261(6):1124-30
pubmed: 25607767
Thorac Cancer. 2018 Aug;9(8):956-966
pubmed: 29893036
Gut Liver. 2019 Feb 27;13(4):394-401
pubmed: 30970448
PLoS One. 2017 Jun 29;12(6):e0180251
pubmed: 28662130
Onco Targets Ther. 2017 Mar 03;10:1363-1373
pubmed: 28424552
Mol Pharmacol. 2017 Sep;92(3):232-239
pubmed: 28356334
Biomed Res Int. 2018 Jun 26;2018:7610154
pubmed: 30046606
World J Gastroenterol. 2017 Feb 21;23(7):1310-1318
pubmed: 28275311
Biomed Res Int. 2014;2014:981261
pubmed: 24963492
Sci Rep. 2019 May 28;9(1):7933
pubmed: 31138856
Medicine (Baltimore). 2019 Feb;98(6):e13921
pubmed: 30732126
Cell Biol Int. 2012 Jun 1;36(6):571-7
pubmed: 22360285
Sci Rep. 2016 Aug 17;6:31423
pubmed: 27530152
J Gastroenterol Hepatol. 2019 Mar;34(3):552-560
pubmed: 30426559
Anal Chem. 2017 Jan 17;89(2):1155-1162
pubmed: 27958721
J Clin Pathol. 2007 May;60(5):510-4
pubmed: 16822877
Cancer Epidemiol Biomarkers Prev. 2013 Jul;22(7):1185-209
pubmed: 23576690
Br J Surg. 2004 Aug;91(8):1055-60
pubmed: 15286970
Cell. 2004 Jun 25;117(7):927-39
pubmed: 15210113
Cancer Sci. 2012 Feb;103(2):233-8
pubmed: 22050045
Anal Chem. 2014 Nov 18;86(22):11349-56
pubmed: 25317565
Br J Cancer. 2008 Feb 12;98(3):547-57
pubmed: 18212745